|
As
of December 31, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive:
SCHEDULE
OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from the conversion of Series B Preferred Stock inclusive of accrued dividends ($6.19 conversion price) |
|
|
292,990 |
|
| Shares from common stock options |
|
|
177,815 |
|
| Shares from common stock warrants |
|
|
323,543 |
|
| Shares from conversion of convertible notes inclusive of accrued interest ($8.00 conversion price) |
|
|
64,126 |
|
| Shares from the conversion of Series A Preferred stock (calculated from liquidation value and assumed conversion price at December 31, 2022 of $3.33 per share) |
|
|
216,577 |
|
As
of December 31, 2021, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive:
| Shares from the conversion of Series B Preferred Stock not inclusive of accrued dividends |
|
|
235,774 |
|
| Shares from common stock options |
|
|
27,815 |
|
| Shares from common stock warrants |
|
|
37,083 |
|
| Shares from conversion of convertible notes not inclusive of accrued interest |
|
|
75,625 |
|
| Shares from the conversion of debentures |
|
|
5,469 |
|
| Shares from the conversion of Series A Preferred Stock (calculated from liquidation value and an assumed conversion price at December 31, 2021 of $6.40 per share) |
|
|
108,231 |
|
|